Big VC Biotech Spending on the Rise for 2012

NOKOMIS, Fla. -- (BUSINESS WIRE) -- As Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), continues to vet investment banks to assist with its capital raise, investors remain optimistic on the returns that new biotech firms can bring. A recent report indicates that venture capital investments in biotech increased by 22 percent to $4.7 billion last year.

The report, published earlier this month by PricewaterhouseCoopers and the National Venture Capital Association, states that the life sciences sector accounted for 27 percent of all venture capital dollars spent nationally in 2011. That upswing lead an overall 22-percent increase in venture capital spending over 2010.

With investors clearly excited about the prospects of biotech, many analysts expect those VC dollars to increase yet again in 2012. That’s terrific news for RBCC. The company is currently in the process of short-listing an investment banking firm in Houston, home of the company’s biosciences division, to assist with potential capital-raise programs.

Once funding is secured, RBCC plans to close an investment opportunity with Nano3D Biosciences (n3D) and other target companies. Nano3D is a fully commercialized company that has developed a breakthrough three-dimensional cell culturing system. The assistance of an investment banking firm in raising capital would allow RBCC to move forward with its acquisition plans and global marketing initiative for n3D.

RBCC seeks to work with Houston firms due to the impressive performance of the area’s biotech sector.

For more information on Rainbow BioSciences, Rainbow Coral’s biotech division, please visit www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.